Polymorphisms of TP53 are markers of bladder cancer vulnerability and prognosis

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1231-1241

  Lin, Hung Yu ^a,b   Yang, Ming Chang ^c,d   Huang, Chun Hsiung ^e   Wu, Wen Jen ^e   Yu, Tsan Jung ^a   Lung, For Wey ^c,f,g  

^a E DA HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI CITY HOSPITAL   (Taiwan)

^g NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Bladder cancer; Invasiveness; Prognosis; TP53 haplotype; Vulnerability

Indexed keywords

PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL EQUATION MODELING; TUMOR INVASION;

BLADDER CANCER; INVASIVENESS; PROGNOSIS; TP53 HAPLOTYPE; VULNERABILITY;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TAIWAN; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84884672311     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.11.031     Document Type: Article

References (36)

1. Lin H.Y., Huang C.H., Wu W.J., et al. TP53 codon 72 gene polymorphism paradox in associated with various carcinoma incidences, invasiveness, and chemotherapy responses. Int J Biomed Sci 2008, 4:248-254.
2. Lung F.W., Lee T.M., Shu B.C., et al. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 2004, 130:728-732.
3. Furihata M., Kurabayashl A., Matsumoto M., et al. Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract. J Pathol 2002, 197:82-88.
4. Chen W.C., Tsai F.J., Wu J.Y., et al. Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol Res 2000, 28:293-296.
5. Horgan A.M., Yang B., Azad A.K., et al. Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol 2011, 6:296-304.
6. Mechanic L.E., Bowman E.D., Welsh J.A., et al. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 2007, 16:214-222.
7. Mahmoudi S., Henriksson S., Corcoran M., et al. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 2009, 33:462-471.
8. Farnebo M. Wrap53, a novel regulator of p53. Cell Cycle 2009, 8:2343-2346.
9. Mahmoudi S., Henriksson S., Farnebo L., et al. Wrap53 promotes cancer cell survival and is a potential target for cancer therapy. Cell Death Dis 2011, 2:e114.
10. Lin H., Huang C.H., Yu T.J., et al. P53 codon72 polymorphism was associated with vulnerability, progression, but not prognosis of bladder cancer in Taiwanese population: An implication of structural equation modeling to manage risks of bladder cancer. Urol Int 2011, 86:355-360.
11. Li C.C., Chang T.H., Wu W.J., et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephronureterectomy in Taiwanese patients. Eur Urol 2008, 54:1127-1134.
12. Gordon D., Finch S.J., Nothnagel M., et al. Power and sample size calculations for case-control genetic association tests when errors are present: Application to single nucleotide polymorphisms. Hum Hered 2002, 54:22-33.
13. Purcell S., Cherny S.S., Sham P.C. Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003, 19:149-150.
14. Sprague B.L., Trentham-Dietz A., Garcia-Closas M., et al. Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis 2007, 28:1680-1686.
15. Chen Y.C., Xu L., Guo Y.L., et al. Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: A preliminary study. Biomarkers 2004, 9:386-394.
16. Lin H.Y., Huang C.H., Wu W.J., et al. Mutation of the p53 tumor suppressor gene in transitional cell carcinoma of the urinary tract in Taiwan. Kaohsiung J Med Sci 2005, 21:57-64.
17. Dumont P., Leu J.I., Della Pietra A.C., et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365.
18. Pim D., Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004, 108:196-199.
19. Siddique M., Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 2006, 25:3489-3500.
20. Kuroda Y., Nakao H., Ikemura K., et al. Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. Oral Oncol 2007, 43:1043-1048.
21. Soulitzis N., Sourvinos G., Dokianakis D.N., et al. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002, 179:175-183.
22. Kuroda Y., Tsukino H., Nakao H., et al. p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett 2003, 189:77-83.
23. Tada M., Furuuchi K., Kaneda M., et al. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001, 22:515-517.
24. Storey A., Thomas M., Kalita A., et al. Role of a p53 polymorphism in the development of human papilloma virus-associated cancer. Nature 1998, 393:229-234.
25. Park J.S., Kim E.J., Lee J.Y., et al. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int J Cancer 2001, 91:822-827.
26. Boldrini L., Gisfredi S., Ursino S., et al. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Invest 2008, 26:168-172.
27. Fay J.C., Wyckoff G.J., Wu C.I. Positive and negative selection on the human genome. Genetics 2001, 158:1227-1234.
28. Gaboli M., Kotsi P.A., Gurrieri C., et al. Mzf1 controls cell proliferation and tumorigenesis. Genes Dev 2001, 15:1625-1630.
29. Amati B., Dalton S., Brooks M.W., et al. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 1992, 359:423-426.
30. Perini G., Diolaiti D., Porro A., et al. In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation. Proc Natl Acad Sci U S A 2005, 102:12117-12122.
31. Laurenti E., Varnum-Finney B., Wilson A., et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 2008, 3:611-624.
32. Knoepfler P.S., Cheng P.F., Eisenman R.N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 2002, 16:2699-2712.
33. Liu N., Wang L., Li X., et al. N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res 2008, 36:5335-5349.
34. Wang D.M., Sevcikova S., Wen H., et al. v-Myb represses the transcription of Ets-2. Oncogene 2007, 26:1238-1244.
35. Janardhanan R., Banik N.L., Ray S.K. N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53. Biochem Pharmacol 2009, 78:1105-1114.
36. Horikawa Y., Nadaoka J., Saito M., et al. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep 2008, 20:49-55.